MNOV - MediciNova, Inc. Summary, Stock Quote and News

7.530 -0.2 (-2.59%)

After Hours 7.53 (%)

Data as of Dec 15, 2019

Prev. Close 7.73
Price Open 7.67
Volume 48,800
Day's Range 7.49 - 7.73
52 Wk Range 6.6801 - 13.37
50 Day Moving Avg. 7.66
PE Ratio 0
Shares Outstanding 43.84M
Market Cap 330.13M

Trade MNOV stock with recommended broker Ally Invest. Commissions as low as $3.95.

Analyst Rating View All Ratings

Date	Research Firm	Action	Current	Target
3/25/19	B. Riley FBR	Assumes	Buy	22.0
3/28/18	B. Riley FBR	Initiates Coverage On	Buy	22.0
8/27/12	McNicoll Lewis Vlak	Terminates

MediciNova Reports Added Analyses From Completed Trial Of MN-166 In ALS Presented At 30th Int'l. Symposium On ALS/MND Benzinga NewsdeskWed, 04 Dec 2019 18:01:58 -0500
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada Charles GrossMon, 28 Oct 2019 05:07:53 -0500
51 Biggest Movers From Friday Lisa LevinMon, 28 Oct 2019 04:27:28 -0500
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of NAFLD and NASH in Japan Charles GrossWed, 23 Oct 2019 05:05:46 -0500
46 Biggest Movers From Friday Lisa LevinMon, 21 Oct 2019 04:37:10 -0500
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Idiopathic Pulmonary Fibrosis in Japan Charles GrossTue, 08 Oct 2019 03:47:09 -0500
28 Healthcare Stocks Moving In Today's Pre-Market Session Lisa LevinFri, 02 Aug 2019 08:07:30 -0500
MediciNova Announces MN-001 Research Collaboration with the National Cerebral and Cardiovascular Disease Research Center in Japan Charles GrossWed, 31 Jul 2019 02:59:42 -0500
MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 30th International Symposium on ALS/MND in Perth, Australia Charles GrossTue, 30 Jul 2019 02:56:16 -0500
28 Healthcare Stocks Moving In Today's Pre-Market Session Lisa LevinFri, 26 Jul 2019 09:09:38 -0500
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

MediciNova Announces Additional Analyses from Completed Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 30th International Symposium on ALS/MND in Perth, Australia Globe NewswireDec 04, 2019
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada Globe NewswireOct 28, 2019
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of NAFLD and NASH in Japan Globe NewswireOct 23, 2019
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Idiopathic Pulmonary Fibrosis in Japan Globe NewswireOct 07, 2019
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in China Globe NewswireSep 30, 2019
MediciNova to Present at the Ladenburg Thalmann 2019 Healthcare Conference in New York Globe NewswireSep 11, 2019
MediciNova to Attend the Morgan Stanley Global Healthcare Conference in New York Globe NewswireAug 29, 2019
MediciNova Announces MN-001 Research Collaboration with the National Cerebral and Cardiovascular Disease Research Center in Japan Globe NewswireJul 30, 2019
MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 30th International Symposium on ALS/MND in Perth, Australia Globe NewswireJul 29, 2019
MediciNova Appoints Kazuko Matsuda to its Board of Directors Globe NewswireJul 24, 2019
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

MediciNova Announces Additional Analyses from Completed Clinical Trial of MN-–66 (ibudilast) ... GuruFocusDec 04, 2019
MediciNova nabs new Canadian patent covering ibudilast Seeking AlphaOct 28, 2019
MediciNova Receives Notice of Allowance for New Patent Covering MN-……– for the Treatment ... GuruFocusOct 23, 2019
MediciNova nabs new patent in Japan for MN-001 Seeking AlphaOct 23, 2019
MediciNova nabs new patent for MN-001 and MN-002 in Japan Seeking AlphaOct 08, 2019
MediciNova Receives Notice of Allowance for New Patent Covering MN-……– and MN-……— ... GuruFocusOct 07, 2019
MediciNova to Present at the Ladenburg Thalmann —…–9 Healthcare Conference in New York GuruFocusSep 11, 2019
MediciNova: Leading The Pack In An MS Subtype Seeking AlphaAug 20, 2019
MediciNova files for $200M mixed shelf Seeking AlphaAug 10, 2019
MediciNova Announces MN-……– Research Collaboration with the National Cerebral and ... GuruFocusJul 30, 2019
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Earnings View Earnings

Q2 2019	EST	Actual	Surprise
EPS:	-0.140	-0.090	0.0500
Rev:		0.00

Q3 2019	EST	Actual	Surprise
EPS:	Expected 2019-12-27
Rev:	Expected 2019-12-27

Company Profile

Brokerage Center

Compare All Online Brokerages

Market Overview

MediciNova, Inc. MNOV:NASDAQ

Analyst Rating View All Ratings

Earnings View Earnings

Company Profile

Brokerage Center

Popular Channels

Tools & Features

About Benzinga

Benzinga Partners

Membership is Free

What are you waiting for? Sign up now!

Free Account Login

Market Overview

Tickers

Articles

Keywords

MediciNova, Inc. MNOV:NASDAQ

Analyst Rating View All Ratings

Earnings View Earnings

Company Profile

Brokerage Center

Popular Channels

Tools & Features

About Benzinga

Benzinga Partners